Skip to main content

GlaxoSmithKline extends InforSense deal

GlaxoSmithKline (GSK) has signed an agreement to continue its use of the Inforsense business and scientific intelligence tools by 800 employees across the organisation.'GSK is one of our key customers and we are looking forward to continued work with the company,' said Jonathan Sheldon, chief scientific officer, InforSense. 'By renewing its commitment to InforSense, GSK will continue to benefit from the productivity gains delivered by the InforSense platform in quickly developing scientific applications.'


Media Partners